<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940511-2-00213</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated April 8, 1994, Drs. Sobol and Royston submitted a revised protocol to the Recombinant DNA Advisory Committee for formal review and approval. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> II. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Dr. Curiel <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated April 13, 1994, Dr. David Curiel of the University of Alabama, Birmingham, Alabama, submitted the human gene transfer protocol entitled: Phase I Trial of a Polynucleotide Vaccine to Human Carcinoembryonic Antigen in Patients with Metastatic Colorectal Cancer to the Recombinant DNA Advisory Committee for formal review and approval. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> III. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Drs. Evans and Robbins <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated April 13, 1994, Drs. C. H. Evans and Paul Robbins of the University of Pittsburgh, Pittsburgh, Pennsylvania, submitted the human gene transfer protocol entitled: Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis to the Recombinant DNA Advisory Committee for formal review and approval. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> IV. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Drs. Heslop, Brenner, and Krance <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated April 6, 1994, Drs. Helen Heslop, Malcolm Brenner, and Robert Krance of the St. Jude Children's Research Hospital, Memphis, Tennessee, submitted the human gene transfer protocol entitled: Use of Double Marking with Retroviral Vectors to Determine Rate of Reconstitution of Untreated and Cytokine Expanded CD34(+) Selected Marrow Cells in Patients Undergoing Autologous Bone Marrow Transplantation to the Recombinant DNA Advisory Committee for formal review and approval. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> V. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Dr. Lyerly <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated April 12, 1994, Dr. H. Kim Lyerly of Duke University Medical Center, Durham, North Carolina, submitted the human gene transfer protocol entitled: A Pilot Study of Autologous Human Interleukin-2 Gene Modified Tumor Cells in Patients with Refractory or Recurrent Metastatic Breast Cancer to the Recombinant DNA Advisory Committee for formal review and approval. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> VI. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Drs. Economou, Glaspy, and McBride <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated April 11, 1994, Drs. James Economou, John Glaspy, and William McBride of the University of California, Los Angeles, California, submitted a human gene transfer protocol entitled: A Phase I Testing of Genetically Engineered Interleukin-7 Melanoma Vaccines to the Recombinant DNA Advisory Committee for formal review and approval. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> VII. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Dr. Freedman <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated March 22, 1993, Dr. Ralph Freedman of M.D. Anderson Cancer Center, Houston, Texas, submitted the human gene transfer protocol entitled: Use of a Retroviral Vector to Study the Trafficking Patterns of Purified Ovarian Tumor Infiltrating Lymphocyte (TIL) Populations Used in Intraperitoneal Adoptive Immunotherapy of Ovarian Cancer Patients: A Pilot Study to the Recombinant DNA Advisory Committee for formal review and approval. At its June 7&hyph;8, 1993, meeting the Recombinant DNA Advisory Committee deferred the protocol until the investigators return to the full Recombinant DNA Advisory Committee with the following:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (1) Data demonstrating efficient transduction of TIL, <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) Sufficient information regarding demonstration of selectivity, i.e., specific trafficking of TIL to tumor,  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (3) Complete statistical analysis, <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (4) Revised Informed Consent document in simplified language, and  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (5) Address concerns about patient responsibility for research-related costs. The motion to defer the protocol pending full Recombinant DNA Advisory Committee review of additional information passed by a vote of 18 in favor, 0 opposed, and no abstentions. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> In a letter dated January 5, 1994, Dr. Freedman submitted a revised protocol to the Recombinant DNA Advisory Committee for formal review and approval. At its March 3&hyph;4, 1994, meeting, the Recombinant DNA Advisory Committee deferred the protocol until the investigator returns to the full Recombinant DNA Advisory Committee with: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (1) A modified protocol, which includes a revised treatment schema that will provide statistically significant information, and  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) A revised Informed Consent document that adequately describes the procedures that will be performed in language understandable to lay persons. The motion to defer the protocol pending full Recombinant DNA Advisory Committee review of the additional information passed by a vote of 12 in favor, 1 opposed, and no abstentions. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> In a letter dated April 13, 1994, Dr. Freedman submitted a revised protocol to the Recombinant DNA Advisory Committee for formal review and approval. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> VIII. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Drs. Deisseroth, Hortobagyi, and Champlin <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated April 12, 1994, Drs. Albert Deisseroth, Gabriel Hortobagyi, and Richard Champlin of the M.D. Anderson Cancer Center, Houston, Texas, submitted the human gene transfer protocol entitled: Use of Safety-Modified Retroviruses to Introduce Chemotherapy Resistance Sequences into Normal Hematopoietic Cells for Chemoprotection During the Therapy of Breast Cancer: A Pilot Trial to the Recombinant DNA Advisory Committee for formal review and approval. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> IX. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Dr. Roth <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            